Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

<p>Prior exposure to systemic treatments may affect treatment outcomes in moderate-to-severe atopic dermatitis (AD).</p> <p>This study aimed to explore the efficacy and safety of Ivarmacitinib (SHR0302) in moderate-to-severe AD patients with or without previous systemic treatments....

Fuld beskrivelse

Saved in:

Bibliografiske detaljer
Hovedforfatter:	Qingchun Diao (5751701) (author)
Andre forfattere:	Ruiling Jia (22654733) (author), Min Li (12799) (author), Peng Zhao (128233) (author), Fang Lu (45632) (author), Qin Zhang (58638) (author), Chunzhu Ning (22680917) (author), Juan Long (4017317) (author), Jiajia Li (184267) (author), Yan Huang (46805) (author), Yuyi Wang (462133) (author)
Udgivet:	2025
Fag:	Medicine Pharmacology Biotechnology Science Policy Biological Sciences not elsewhere classified Ivarmacitinib moderate-to-severe atopic dermatitis previous systemic treatments efficacy safety
Tags:	Tilføj Tag Ingen Tags, Vær først til at tagge denne postø!

Vær først til at give en kommentarø!

Efficacy and safety of Ivarmacitinib in moderate-to-severe atopic dermatitis patients with or without previous systemic treatments: a post-hoc analysis of a phase III trial

Lignende værker